Understanding the biological and clinical correlates of delirium: Development of Reporting Essentials for Delirium bioMarker Studies (REDEEMS) by Amgardt-Duff, Ingrid K. V.
 1 
 
Understanding the biological and clinical 
correlates of delirium: Development of Reporting 




Ingrid Amgarth-Duff, BBiomedSc (Hons) 
 
Thesis submitted in fulfilment of the degree of 




University of Technology Sydney 
 2 























































































































































































































Delirium is a common, serious and complex neurocognitive condition that is 
associated with negative impacts for both the person with delirium and their 
family/carers. Despite the significant burden, the pathophysiology of delirium remains 
unclear. To improve our understanding of delirium pathophysiology, robust delirium 
biomarker studies with optimal reporting are urgently needed to ensure each of these 
studies contribute to accelerate our knowledge. 
Aim 
To evaluate and optimize the methodological approaches in research evaluating 
biological and clinical correlates of delirium and underlying conditions.  
Design 
A multiple methods project, involving three discreet but inter-related studies 
conducted over three stages.  
Methods 
Study 1 was a systematic review of the overlap of delirium and advanced cancer-
related syndrome biomarkers as an ‘examplar’ of the potential for interaction between 
the underlying condition and delirium; Study 2a was a three-stage modified Delphi 
study with delirium researchers and study 2b was a follow-up consensus meeting to 
generate a reporting guideline specific to delirium biomarker studies (REDEEMS). 
Study 3 comprised a series of semi-structured interviews which sought delirium 




The systematic review identified considerable overlap of delirium and advanced 
cancer biomarkers, with 41 biomarkers that had been studied in relation to both 
delirium and either an advanced cancer-related syndrome or prognosis. It also revealed 
a significant gap in the consistency and reporting of delirium biomarker studies. 
Considering this unexpected finding of poor quality, a drive to improve the methods 
of reporting delirium biomarker studies was warranted. The international Delphi study 
and consensus meeting (study 2) revealed a total of nine items which were deemed 
critical elements by delirium researchers for inclusion in the REDEEMS guideline. 
Finally, the third qualitative study identified a range of factors that contribute to the 
challenges and overall quality of delirium biomarker research. Delirium researchers 
concurred that delirium biomarker research is both an extremely difficult and complex 
field. and that the quality of reporting delirium biomarker research is poor, which 
contribute to lack of progress in scientific understanding. Analysis revealed two major 
themes and ten sub-themes, outlining key considerations to advance the field of 
delirium biomarker research. The major themes were: 1) Practical and scientific 
challenges of delirium biomarker research: stagnation versus driving improved 
methods and reporting; and 2) Valuing delirium research through investment and 
collaboration. 
Conclusion  
The REDEEMS guideline is the first reporting guideline specific for delirium 
biomarker studies aligned with impacts of reporting guidelines in other research 
methods. It aims to guide improvements in consistency and transparency of reporting 
future biomarker studies in delirium, conceivably permitting accurate replication and 
synthesis, and improving scientific rigor in the field. A collaborative effort to increase 
 xiii 
awareness of, and improve research funding for delirium is needed, along with 
increased education and training in delirium biomarker methodology. These 
advancements will lead to significant improvement of our understanding of delirium 
pathophysiology and ultimately improve outcomes for people with delirium. 
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CAM Confusion Assessment Method 
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Glossary of terms  
Advanced cancer  Inclusive of stage III cancer (locally advanced with spread to nearby 
tissues or lymph nodes) and Stage IV cancer (metastatic disease).1 
Anorexia cachexia  A complex metabolic syndrome of involuntary weight loss associated 
with cancer and some other palliative conditions.2 
Biomarker  A biological molecule found in blood, other body fluids, or tissues that 
is a sign of a normal or abnormal process, or of a condition or 
disease.3  
Cancer prognosis  The likely outcome or course of the disease; the chance of recovery 
or recurrence. Cancer prognosis is assessed by cancer-specific 
survival, overall survival, progression free survival or relative 
survival.4   
Cancer-related cognitive 
impairment  
Cognitive impairment that is commonly experienced by cancer 
patients and those in remission. The cognitive domains most 
commonly affected are memory, concentration, information 
processing speed and executive function.5 
Cancer-related fatigue A distressing, persistent, subjective sense of physical, emotional, 
and/or cognitive tiredness or exhaustion related to cancer and/or 
cancer treatment that is not proportional to recent activity and 
interferes with usual functioning.6  
Cancer-related pain An unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such 
damage.7 
Classical Delphi Methodology  A research methodology with an aim to achieve consensus on a 
research question, using an expert panel, in an iterative and 
controlled survey process.8 
Delirium 
 
A neurocognitive disorder, characterised by acute disturbance to 
attention, awareness and cognition, affecting memory, language, 
visuospatial ability, orientation and perception.9  
e-Delphi A Delphi research method that involves the distribution of a survey 
electronically to panellists via email.  
Hyperactive delirium 
 
Delirium subtype where the patient has an increased level of 
psychomotor activity. There may also be lability of mood, agitation 
and resistance to medical care.9 
Hypoactive delirium 
 
Delirium subtype where the patient has a decreased level of 
psychomotor activity, along a continuum from lethargy to stupor.9 
Incidence 
 
The occurrence of new cases of a disease in a population over a 
specified period of time.10 
Mixed delirium 
 
Delirium subtype where the patient has either a normal or fluctuating 
level of psychomotor activity.9  
Modified Delphi  Describes any methodological variation of the Classical Delphi 
method described by Dalkey and Helmer (1962).11  
Morbidity Non-fatal event.  
Mortality Fatal event/death. 
Multiple methods The use of two or more research methods in one research project.12 
Persistent delirium  Full syndromal delirium at the time of admission (or shortly after 
admission) that continues to meet the criteria for delirium at the time 
of discharge or beyond.13 
Prevalence The proportion of a persons in a population who have a particular 
disease or attribute at a specified point in time or over a specified 
period of time.10 
Point prevalence  The proportion of persons with a particular disease or attribute at a 
particular point in time (on a particular date).10 
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Prodromal delirium Manifestation of symptoms such as changes to concentration, mood 
(irritability, anxiety, depression), sleep patterns (including vivid 
dreaming), cognition (e.g. disorientation), tiredness or noise 
sensitivity, that can occur in the hours, days or weeks prior to full 
syndromal delirium.14  
Qualitative research  A means for exploring and understanding the meaning of individuals 
or groups ascribed to a social or human problem.15 
Quantitative research  A means for testing objective theories by examining the relationship 
among variables.15 
Reporting guideline  A checklist, flow diagram, or explicit text to guide authors in reporting 
a specific type of research, developed using explicit methodology.16 
Sickness behaviour  The coordinated set of behavioural changes that develop in sick 
individuals during the course of an infection. Sickness behavior is also 
seen in other illness including cancer.17,18 
Sub-syndromal delirium 
 
Presence of one or more symptoms of delirium, where the patient 
does not meet the criteria for delirium.19 Termed ‘attenuated delirium 
syndrome’ by the DSM-5.9 
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